Cent
Category: AI in Healthcare
An AI-powered preventive healthcare intelligence platform focused on early detection of cancer, cardiac, neurological, and metabolic (CCNM) diseases before symptoms appear, using multi-modal imaging, biomarkers, and AI synthesis. Cent was founded in 2025. Based in Bengaluru, India. Team size: N/A. Total funding raised: $5.0M. Latest round: Seed. Key investors include OneFlow Holdings, South Park Commons.
- Founded
- 2025
- Headquarters
- Bengaluru, India
- Team size
- N/A
- Total funding
- $5.0M
Value proposition
Detects life-threatening diseases at 'Stage 0' or 'Stage 1' when survival rates are exponentially higher, through comprehensive multi-modal screening (full-body MRI, CT, DEXA, 120+ biomarkers, genetics) with AI-powered synthesis, identifying 300+ conditions responsible for 80%+ of premature deaths with 26% clinically meaningful detection rate in initial scans.
Products and solutions
Cent Check (365-day preventive health membership), CCNM™ Protocol (Cardiac, Cancer, Neurological, Metabolic Screening), Annual Full-Body MRI, CT Calcium and Lung Screening, DEXA, ECG, 2D Echo, Spirometry and Mammography for Women Over 45, 100+ Blood and Urine Biomarkers with At-Home Collection, Six-Month Checkpoint: Repeat Biomarkers and DEXA, with ECG and Echo if Recommended, Up to Four Doctor Consultations per Year, Cent App with Tru10™ Organ-Level Scores, Health Trends and Personalized AI Companion, Genetics Module (Optional Add-On), Doctor-Reviewed Reports and Personalized Health Plan
Unique value
Pioneers 'zero-symptom' diagnostics focused exclusively on pre-symptomatic disease detection at Stage 0/Stage 1, combining full-body MRI, low-dose CT, DEXA, ECG, 120+ biomarkers, and optional genetic testing into a single standardized workflow. Proprietary CCNM™ protocol targets 300+ conditions responsible for 80%+ of premature deaths. Achieved 26% clinically meaningful detection rate in 1,500+ initial scans, with 4% identifying critical conditions in completely asymptomatic individuals.
Target customer
Direct-to-consumer (D2C) asymptomatic individuals aged 30+ seeking proactive health screening; health-conscious adults focused on preventive care and longevity; high-net-worth individuals and executives prioritizing comprehensive health monitoring
Industries served
Preventive Healthcare, Medical Diagnostics, Healthcare AI, Health Screening & Wellness, Medical Imaging, Diagnostic Imaging Centers
Technology advantage
Integrates advanced multi-modal diagnostics (whole-body MRI, cardiac CT, DEXA, comprehensive biomarkers) with AI-powered synthesis and medical specialist validation into a unified D2C platform. Unlike traditional health checkups that use tiered packages and limited imaging (typically ultrasound only), Cent offers comprehensive imaging with no tiers—one complete scan at ₹27,500-₹40,000 early access price. The Tru10™ scoring system provides organ-level risk assessments, enabling personalized health optimization. Single-purpose, standardized workflow designed specifically for CCNM condition detection ensures consistency and accuracy across all centers.
How they differentiate
Cent differentiates through its proprietary CCNM™ protocol (Cardiac, Cancer, Neurological, Metabolic) designed specifically for the Indian market, integrating full-body MRI, low-dose CT, DEXA, ECG, and 120+ biomarkers with AI-driven synthesis into a single standardized D2C workflow. Unlike global competitors focused on Western markets, Cent offers comprehensive multi-modal screening at ₹27,500-₹40,000 (early access pricing), significantly more affordable than Western counterparts ($2,000-2,500). The platform uniquely targets 300+ conditions responsible for 80%+ of premature deaths with a 26% clinically meaningful detection rate in asymptomatic individuals.
Main competitors
Prenuvo, Function Health, Neko Health
Key partnerships
OneFlow Holdings (Shashank ND's family office - Lead Investor), South Park Commons (Investor - US-based VC firm), Siemens Healthineers (Strategic partnership for advanced diagnostic imaging), Healthcare provider partnerships for specialized imaging centers (in development), Expansion partnerships planned for Pune and Hyderabad markets, Clinical validation partnerships with radiologists and medical specialists, Philips (Strategic collaboration announced September 2, 2026, for AI-enabled MRI, preventive imaging protocols, clinical workflows and early risk detection)
Notable customers
Bhargav (featured testimonial - early detection provided reassurance), Nidhi (featured testimonial - family history prompted proactive screening), Vineet (featured testimonial - co-founder who switched from traditional checkups)
Major milestones
Founded in 2023 by Practo co-founder Shashank ND with experienced team from Lenskart and Ola Electric, Developed proprietary CCNM™ protocol for screening 300+ conditions, Conducted 1,500+ scans during initial operations with strong detection rates, Raised $5M seed funding from OneFlow Holdings and South Park Commons (Mar 2026), Official launch announced Mar 6, 2026 following months of live operations, Opened flagship clinical prevention centre in Bengaluru (Apr 2026) with advanced diagnostic capabilities, Deepened strategic partnership with Siemens Healthineers for advanced imaging (Apr 2026), Scaled to 3,000+ scans completed across partner network and owned centre
Growth metrics
Conducted 3,000+ scans with 1 in 3 members discovering major risks and 4% finding critical conditions in asymptomatic individuals; achieved $2M ARR with 50% month-on-month growth
Market positioning
Early-stage D2C preventive healthcare intelligence platform positioning as India's first dedicated 'zero-symptom' diagnostic service. Targets health-conscious individuals aged 30+, high-net-worth individuals, and executives seeking proactive health screening. Competes in the emerging preventive healthcare segment in India, distinguishing itself from traditional health checkups through comprehensive imaging and AI-powered early disease detection.
Geographic focus
India - Operating centres in Bengaluru, Mumbai and Delhi NCR (Gurugram); further expansion planned, including Pune and Hyderabad.
Patents and IP
No registered patents publicly disclosed as of March 2026. Proprietary technologies include CCNM™ protocol and Tru10™ organ-wise scoring system protected as trade secrets and intellectual property.
About the founder
Founder & CEO of Practo (2008-2026), India's leading healthcare technology platform; elevated to Managing Director and Executive Chairman in September 2026, with Jagnoor Singh appointed CEO effective September 1, 2026. Founded Practo as a college project and scaled it to serve 200M+ users across 15 countries. Expertise in healthcare technology, digital health platforms, and AI-driven healthcare solutions. Featured in Forbes 30 Under 30 Asia (2017). Economic Times Startup of the Year recognition. Now Founder & Chair of Cent, focused on AI-powered preventive health intelligence.
Latest news about Cent
- Cent, the AI‑led healthtech venture founded by Practo co‑founder Shashank ND, just closed a $5 M seed round backed by OneFlow Holdings and South Park Commons. The funding will fuel its direct‑to‑consu
- Bengaluru-based healthtech startup Cent raised $5 million in seed funding to scale its AI-powered early disease detection platform. Founded by Practo co-founder Shashank ND, Cent's proprietary CCNM pr
More AI in Healthcare companies
Official website: https://www.cent.health/